Patent · US Active

Anti-DLL3 antibodies and drug conjugates for use in melanoma

US10308721B2 · kind B2 · utility

6Cited by
93References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 23, 2015
Grant dateJun 4, 2019
Priority date—
Expiry dateJun 30, 2035

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.